Flat View
By Year
Monthly View
By Month
Weekly View
By Week
Daily View
Jump to month Jump to month
Jump to month
By Categories

OG Westchester Weekly Speaker Program

Tuesday, September 01, 2020  11:00am  12:00pm


The Old Guard of Westchester is a not-for-profit organization, with roots that go back to 1954.  Old Guard members are residents of Westchester County and neighboring communities.  We are retired or semi-retired men who had careers such as businessmen, lawyers, doctors, managers, financiers, writers, teachers, and communication specialists.

We meet every Tuesday at the Ethical Culture Society building in White Plains to socialize and listen to guest speakers on topics including local, regional and national social issues, economic and political topics, medicine and other science related subjects.

During the New York State on PAUSE time period, the Old Guard of Westchester will be conducting our weekly speaker session via Zoom Virtual Meetings. For information regarding attendance at a specific event, contact:  Stephen Loewengart --- (914) 761-3384

For more information general information - Old Guard of Westchester

Name of Speaker:   Dr. Jill Horowitz, PhD

Title of Talk:        COVID Therapy and Protection with Monoclonal Antibodies from Recovered Patients

About the Speaker:  Dr. Horowitz is the Executive Director Strategic Operations at Rockefeller University in NYC. Highly successful life sciences global business leader with >10 years in pharma BD&L and product development and 6 years in US government healthcare regulation. Deep understanding of strategy and decision-making in the healthcare industry, honed by years of experience working with large payers to develop and commercialize new products successfully in the managed care setting. 


Location     7 Saxon Wood Road, White Plains, New York
Extra Info    Based on successful therapy and prevention for other viral diseases, we are seeking a treatment and prevention against COVID-19 using monoclonal antibodies from recovered patients. We isolated antibodies against SARS-CoV-2 from patients who had recovered from COVID-19 during the peak of the pandemic in the New York City area. We were able to identify and clone a cocktail of 2 highly potent monoclonal antibodies that neutralize different, non-overlapping parts of the spike protein on the surface of the virus. These antibodies are currently being manufactured and tested in animals and are expected to begin human trials in Q4 2020.